The national adverse event reporting system that helps the FDA flag dangerous side effects was of little use in this case because the ailments possibly caused by Vioxx -- heart attacks and strokes -- are so common.
That means Vioxx results cannot automatically be extended to Celebrex and Bextra, which are in the Cox-2 classification with Vioxx but are not identical to it.
Now research lab director Peter Kim and general counsel Kenneth Frazier were flying to Boston to tell one of the men most responsible for Vioxx's success that Merck would be pulling the drug in two days.
